AbbVie adds to elagolix optimism as Allergan stumbles

23 August 2018

US drugmaker AbbVie (NYSE: ABBV) rubbed salt into the wounds of Ireland-incorporated company Allergan (NYSE: ABBV) on Wednesday by presenting positive top-line data from a Phase III extension study of elagolix in women with uterine fibroids.

This came shortly after Allergan had announced that the US Food and Drug Administration (FDA) had issued a complete response letter relating to its New Drug Application (NDA) for Esmya (ulipristal acetate; UPA) for the treatment of abnormal uterine bleeding in women with uterine fibroids.

AbbVie, which is developing elagolix in partnership with Neurocrine Biosciences (Nasdaq: NBIX), now has a strong evidence base from Phase III trials to show the efficacy of its treatment in uterine fibroids. The latest data shows that it reduces heavy menstrual bleeding for up to 12 months when used in combination with low-dose hormone therapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK